Cost of Implementing an Evidence-Based Intervention to Support Safer Use of Antipsychotics in Youth
- PMID: 37261566
- DOI: 10.1007/s10488-023-01273-y
Cost of Implementing an Evidence-Based Intervention to Support Safer Use of Antipsychotics in Youth
Abstract
To estimate the cost of implementing a clinical program designed to support safer use of antipsychotics in children and adolescents (youth) age 3-17 years at the time of initiating an antipsychotic medication. We calculate the costs of implementing a psychiatric consultation and navigation program for youth prescribed antipsychotic medications across 4 health systems, which included an electronic health record (EHR) decision support tool, consultation with a child and adolescent psychiatrist, and up to 6 months of behavioral health care navigation, as well as telemental health for patients (n = 348). Cost data were collected for both start-up and ongoing intervention phases and are estimated over a 1-year period. Data sources included study records and time-in-motion reports, analyzed from a health system perspective. Costs included both labor and nonlabor costs (2019 US dollars). The average total start-up and ongoing costs per health system were $34,007 and $185,174, respectively. The average total cost per patient was $2,128. The highest average ongoing labor cost components were telemental health ($901 per patient), followed by child and adolescent psychiatrist consultation ($659), and the lowest cost component was primary care/behavioral health provider time to review/respond to the EHR decision support tool and case consultation ($24). For health systems considering programs to promote safer and targeted use of antipsychotics among youth, this study provides estimates of the full start-up and ongoing costs of an EHR decision support tool, psychiatric consultation service, and psychotherapeutic services for patients and families.Trial registration: Clinicaltrials.gov, NCT03448575.
Keywords: Antipsychotics; Children; Cost; Quality improvement; Youth.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Safer use of antipsychotics in youth (SUAY) pragmatic trial protocol.Contemp Clin Trials. 2020 Dec;99:106184. doi: 10.1016/j.cct.2020.106184. Epub 2020 Oct 20. Contemp Clin Trials. 2020. PMID: 33091587 Free PMC article.
-
Developing home-based telemental health services for youth: Practices from the SUAY Study.J Telemed Telecare. 2021 Feb;27(2):110-115. doi: 10.1177/1357633X19863208. Epub 2019 Jul 25. J Telemed Telecare. 2021. PMID: 31342851
-
Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer Use of Antipsychotics in Youth (SUAY) Clinical Trial.J Am Acad Child Adolesc Psychiatry. 2022 Jan;61(1):93-102. doi: 10.1016/j.jaac.2021.04.010. Epub 2021 May 4. J Am Acad Child Adolesc Psychiatry. 2022. PMID: 34256967 Free PMC article. Clinical Trial.
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
Youth violence intervention programme for vulnerable young people attending emergency departments in London: a rapid evaluation.Health Soc Care Deliv Res. 2023 Jul;11(10):1-122. doi: 10.3310/JWKT0492. Health Soc Care Deliv Res. 2023. PMID: 37470144
References
-
- Akincigil, A., Mackie, T. I., Cook, S., Hilt, R. J., & Crystal, S. (2020). Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children. Health Services Research, 55(4), 596–603. https://doi.org/10.1111/1475-6773.13297 - DOI - PubMed - PMC
-
- Barclay, R. P., Penfold, R. B., Sullivan, D., Boydston, L., Wignall, J., & Hilt, R. J. (2017). Decrease in statewide antipsychotic prescribing after implementation of child and adolescent psychiatry consultation services. Health Services Research, 52(2), 561–578. https://doi.org/10.1111/1475-6773.12539 - DOI - PubMed - PMC
-
- Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D., Daugherty, J., . . . Ray, W. A. (2012). Antipsychotics and the risk of type 2 diabetes in children and youth. Pharmacoepidemiology and Drug Safety, 21, 166–166. Retrieved from <Go to ISI>://WOS:000308131701341
-
- Bowser, D. M., Henry, B. F., & McCollister, K. E. (2021). Cost analysis in implementation studies of evidence-based practices for mental health and substance use disorders: A systematic review. Implementation Science. https://doi.org/10.1186/s13012-021-01094-3 - DOI - PubMed - PMC
-
- Bushnell, G. A., Crystal, S., & Olfson, M. (2021). Trends in antipsychotic medication use in young privately insured children. Journal of the American Academy of Child and Adolescent Psychiatry, 60(7), 877–886. https://doi.org/10.1016/j.jaac.2020.09.023 - DOI - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical